-
Seven patients were identified when DAP-ASBL therapy was used to eradicate persistent MRSA bacteremia. Isolates from 3 patients were available for in vitro study.
-
In this issue: FDA issues multiple drug safety alerts; ARBs and cancer risk; and FDA actions.
-
The National Medication Error Reporting Program (operated by the Institute for Safe Medication Practices [ISMP]) recently issued an alert on the potential risk of medication errors associated with dosing colistimethate for injection.
-
-
The American Medical Association convened the biannual House of Delegates meeting in Chicago in June with more than 500 delegates from a variety of societies and organizations.
-
Family history of cancer changes significantly between the ages of 30 and 50 years. Therefore, it is recommended that family history should be updated at least every 5 to 10 years to appropriately inform recommendations for cancer screening.
-
Vitamin D deficiency was found to be present in almost all patients entering with acute myocardial infarctions in a 20-hospital multicenter study.
-
The first orally administered factor XA inhibitor has been approved by the FDA for the prevention of deep vein thrombosis (DVT). Rivaroxaban was developed by Bayer and is marketed in this country by Janssen Pharmaceuticals as Xarelto.
-
Interpret the rhythm strip shown above. Does it represent 2nd degree AV block, Mobitz Type II? Can you be sure?
-
A systematic review covering 48 years gives pregabalin (Lyrica) Level A evidence for the treatment of diabetic neuropathy. Gabapentin, sodium valproate, amitriptyline, venlafaxine, and duloxetine may be as effective but only receive a Level B recommendation based on the quality of the studies.
